Botulinum toxin in hemifacial spasm: Revisited

Singh, Shalendra

doi:10.4103/0970-0358.113746

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is therefore not the therapy of first choice in most cases 9 . Botulinum toxin type A (BTX-A) has been used to treat HFS since the 1980s and provides symptom relief and improved quality of life in about 85% to 95% of cases 10 . It is currently considered the gold standard for treatment of HFS as it can be administered in outpatient units, is less invasive than other therapies, and is well tolerated 11 .…”

mentioning

confidence: 99%

Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

Batisti

Kleinfelder

Galli

et al. 2017

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Hemifacial spasm (HFS) is a craniofacial movement disorder characterized by involuntary contractions of the muscles on one side of the face 1 . The most common site for the contractures is the orbicularis oculi muscle, but the corrugator supercilii, frontalis muscle, orbicularis oris, zygomaticus major and platysma can also be affected 2 . The condition is believed to be mainly due to a peripheral dysfunction of the facial nerve, occasionally associated with nerve compression by a blood vessel or tumor 3,4 . The pathophysiology, however, has yet to be fully elucidated as the condition can occur in the absence of structural alterations 3 . In a recent study, Wilkinson and Kaufmann 5 showed that HFS may be associated with central nervous system changes. Accordingly, one previous study from our group found similar profiles of obsessive and psychiatric symptoms in cases of HFS and blepharospasm, which is recognized as a movement disorders of A total of 550 BTX-A injections were administered to 100 HFS patients. Results: Mean duration of improvement following each injection session was 3.1 months, mean latency to detection of improvement was 7.1 days and mean success rate was 94.7%. Patients were evaluated at an interval of 5.8 months after each application. Adverse effects, which were mostly minor, were observed in 37% of the patients at least once during follow-up. The most frequent was ptosis (35.1%). Conclusion: Treatment of HFS with BTX-A was effective, sustainable and safe and had minimal, well-tolerated side effects.

show abstract

mentioning

confidence: 99%

Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

Batisti

Kleinfelder

Galli

et al. 2017

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…For a long time, BTX has only been used in cosmetic dermatology. Since the 1980s, botulinum toxin type A (BTXA) has been used to treat HFS and provide symptom relief and improved quality of life in about 85 to 95% of the cases ( 6 ). Recently, botulinum toxin A (BTXA) has been introduced as a safe and effective therapeutic option for HFS ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

Postoperative ecchymoma of eyelid after botulinum toxin injection for hemifacial spasm: a case report

Guo

Wang

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

Hemifacial spasm (HFS) is a rare movement disorder characterized by involuntary muscle contractions on one side of the face. Compared to the high therapeutic effect, adverse effects of botulinum toxin treatment for HFS occurred rarely. However, managing HFS patients who are also taking antithrombotic drugs poses a challenge. Here, we present a case of postoperative ecchymoma of the eyelid following a botulinum toxin injection in a patient receiving daily vinpocetine and aspirin antiplatelet therapy. This case highlights the importance of considering the potential risks and formulating a treatment plan that maximizes benefit while minimizing complications in HFS patients undergoing botulinum toxin injections and taking antithrombotic medications. To the best of our knowledge, this is the first reported case of postoperative ecchymoma of the eyelid following a botulinum toxin injection. Further research and additional case reports are needed to better understand the management strategies for this patient population.

show abstract

Evaluation of stigmatization in hemifacial spasm and quality of life before and after botulinum toxin treatment

et al. 2018

View full text Add to dashboard Cite

Hemifacial spasm (HFS) is a chronic disease that is characterized by involuntary tonic and clonic contractions of the muscles innervated by the ipsilateral facial nerve. Botulinum toxin (BTX) is the most effective medical treatment of this condition. The aim of our study was to evaluate stigma among patients diagnosed with HFS and to search quality of life and depression before and after BTX injection. Seven self-rating items (HFS-7) and seven questions related to stigmatization were administered to HFS patients. Participants also answered SF-36 health outcome measure and Beck depression inventory before and 4 weeks after the routine BTX injection. The severity of HFS was graded based on a five-point scale. Descriptive statistics and paired t test were applied. The level of significance was set at α = 0.05. Fourty HFS patients were prospectively included. Twenty-one (%52.5) were female and nineteen were male (47.5%) with a mean age of 57.1 (SD = 12.13; min-max = 27-78). 60% (n: 24) of patients were feeling themselves different from people without HFS. Beck depression inventory scores improved after BTX injection significantly (p < 0.05). All domains of SF-36 showed positive improvement after BTX injections. The improvement in general health perception, physical functioning, and vitality was statistically significant (p < 0.05). Although more than half of the patients felt themselves different from people without HFS, treatment of HFS with BTX significantly improved mental health and physical health, and depressive symptoms of the patients.

show abstract

Botulinum toxin in hemifacial spasm: Revisited

Cited by 4 publications

References 4 publications

Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

Postoperative ecchymoma of eyelid after botulinum toxin injection for hemifacial spasm: a case report

Evaluation of stigmatization in hemifacial spasm and quality of life before and after botulinum toxin treatment

Contact Info

Product

Resources

About